2025年4月5日 周六
首页 > 按月查看>2020年第8月 >688-691, 706
PDF 导出
糖尿病肾病诊断与治疗新进展
作者:
作者单位:

(中南大学湘雅二医院代谢内分泌科 糖尿病免疫学教育部重点实验室 国家代谢性疾病临床医学研究中心,湖南省长沙市 410011)

作者简介:

刘裔凯,博士研究生,研究方向为糖尿病的诊治,E-mail为ervin03@csu.edu.cn。通信作者周智广,主任医师,教授,博士研究生导师,研究方向为糖尿病与免疫,E-mail为zhouzhiguang@csu.edu.cn。

基金项目:

国家重点研发计划(2016YFC1305000,2016YFC1305002)；湖南省自然科学基金面上项目(2018JJ2573)；湖南省科技重大专项(2017SK1020)


Progress in diagnosis and treatment of diabetic nephropathy
Author:
  • LIU Yikai

    LIU Yikai

    Department of Metabolism and Endocrinology & Key Laboratory of Diabetes Immunology, Ministry of Education & National Clinical Research Center for Metabolic Diseases, the Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
    在知网中查找
    在百度中查找
    在本站中查找
  • LUO Shuoming

    LUO Shuoming

    Department of Metabolism and Endocrinology & Key Laboratory of Diabetes Immunology, Ministry of Education & National Clinical Research Center for Metabolic Diseases, the Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
    在知网中查找
    在百度中查找
    在本站中查找
  • DENG Min

    DENG Min

    Department of Metabolism and Endocrinology & Key Laboratory of Diabetes Immunology, Ministry of Education & National Clinical Research Center for Metabolic Diseases, the Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
    在知网中查找
    在百度中查找
    在本站中查找
  • ZHOU Zhiguang

    ZHOU Zhiguang

    Department of Metabolism and Endocrinology & Key Laboratory of Diabetes Immunology, Ministry of Education & National Clinical Research Center for Metabolic Diseases, the Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
    在知网中查找
    在百度中查找
    在本站中查找
Affiliation:

Department of Metabolism and Endocrinology & Key Laboratory of Diabetes Immunology, Ministry of Education & National Clinical Research Center for Metabolic Diseases, the Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China)

  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献
    • |
  • 相似文献
    • |
  • 引证文献
    • |
    摘要:

    糖尿病是一组由环境与遗传等多种病因共同引起的以糖代谢紊乱为特征的代谢性疾病。糖尿病肾病(DN)是糖尿病患者最常见、最严重的慢性合并症。目前,糖尿病肾病约占糖尿病患者的40％,是全世界慢性肾病的主要原因。中国已是世界第一糖尿病大国,也是糖尿病肾病大国。本文就糖尿病肾病诊断与治疗方面的新研究进展进行综述,旨在提供有关DN诊断和治疗的最新信息。

    Abstract:

    Diabetes is a group of metabolic diseases characterized by disorders of glucose metabolism, which are caused by a variety of environmental and genetic causes. Diabetic nephropathy (DN) is the most common and severe chronic comorbidity in patients with diabetes. At present, diabetic nephropathy accounts for about 40% of diabetic patients, and is the main cause of chronic kidney disease (CKD) worldwide. At present, China is already the world's largest country with diabetes and a country with diabetic nephropathy. This article reviews the new research progress in the diagnosis and treatment of diabetic nephropathy. Designed to provide the latest information on DN diagnosis and treatment.

    参考文献
    [1] Tuttle KR, Bakris GL, Bilous RW, et al.Diabetic kidney disease:a report from an ADA Consensus Conference.Diabetes Care, 4,7(10):2864-2883.
    [2] Nugent RA, Fathima SF, Feigl AB, et al.The burden of chronic kidney disease on developing nations:a 21st century challenge in global health.Nephron Clin Pract, 1,8(3):c269-c277.
    [3] de Gaetano M, McEvoy C, Andrews D, et al.Specialized pro-resolving lipid mediators:modulation of diabetes-associated cardio-, reno-, and retino-vascular complications.Front Pharmacol, 8,9:1488.
    [4] American Diabetes Association.Standards of medical care in diabetes-2016:summary of revisions.Diabetes Care, 6,9(S1):S4-S5.
    [5] de Boer IH, Rue TC, Cleary PA, et al.Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria:an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort.Arch Intern Med, 1,1(5):412-420.
    [6] American Diabetes Association.7.Diabetes technology:standards of medical care in diabetes-2019.Diabetes Care, 9,2(S1):S71-S80.
    [7] Tziomalos K, Athyros VG.Diabetic nephropathy:new risk factors and improvements in diagnosis.Rev Diabet Stud, 5,2(1-2):110-118.
    [8] Perkins BA, Ficociello LH, Silva KH, et al.Regression of microalbuminuria in type 1 diabetes.N Engl J Med, 3,8(23):2285-2293.
    [9] Hovind P, Tarnow L, Rossing P, et al.Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes:inception cohort study.BMJ, 4,8(7448):1105.
    [10] Alicic RZ, Rooney MT, Tuttle KR.Diabetic kidney disease:challenges, progress, and possibilities.Clin J Am Soc Nephrol, 7,2(12):2032-2045.
    [11] Elley CR, Robinson T, Moyes SA, et al.Derivation and validation of a renal risk score for people with type 2 diabetes.Diabetes Care, 3,6(10):3113-3120.
    [12] De Silva PM, Mohammed AK, Eakanayake EM, et al.Urinary biomarkers KIM-1 and NGAL for detection of chronic kidney disease of uncertain etiology (CKDu) among agricultural communities in Sri Lanka.PLoS Negl Trop Dis, 6,0(9):e4979.
    [13] Ichimura T, Bonventre JV, Bailly V, et al.Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury.J Biol Chem, 8,3(7):4135-4142.
    [14] Humphreys BD, Xu F, Sabbisetti V, et al.Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis.J Clin Invest, 3,3(9):4023-4035.
    [15] Alicic RZ, Rooney MT, Tuttle KR.Diabetic kidney disease:challenges, progress, and possibilities.Clin J Am Soc Nephrol, 7,2(12):2032-2045.
    [16] Mishra J, Ma Q, Prada A, et al.Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury.J Am Soc Nephrol, 3,4(10):2534-2543.
    [17] Garg V, Kumar M, Mahapatra HS, et al.Novel urinary biomarkers in pre-diabetic nephropathy.Clin Exp Nephrol, 5,9(5):895-900.
    [18] Mitsnefes MM, Kathman TS, Mishra J, et al.Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease.Pediatr Nephrol, 7,2(1):101-108.
    [19] Simpson K, Wonnacott A, Fraser DJ, et al.MicroRNAs in diabetic nephropathy:from biomarkers to therapy.Curr Diab Rep, 6,6(3):35.
    [20] Nassirpour R, Raj D, Townsend R, et al.MicroRNA biomarkers in clinical renal disease:from diabetic nephropathy renal transplantation and beyond.Food Chem Toxicol, 6,8(Pt A):73-88.
    [21] Trionfini P, Benigni A, Remuzzi G.MicroRNAs in kidney physiology and disease.Nat Rev Nephrol, 5,1(1):23-33.
    [22] Zhang Y, Zhang S, Wang G.Metabolomic biomarkers in diabetic kidney diseases:a systematic review.J Diabetes Complications, 5,9(8):1345-1351.
    [23] American Diabetes Association.5.Glycemic targets.Diabetes Care, 6,9(S1):S39-S46.
    [24] Muskiet MH, Smits MM, Morsink LM, et al.The gut-renal axis:Do incretin-based agents confer renoprotection in diabetes?.Nat Rev Nephrol, 4,0(2):88-103.
    [25] American Diabetes Association.Microvascular complications and foot care.Diabetes Care, 6,9(S11):S72-S80.
    [26] Brem AS, Morris DJ, Gong R.Aldosterone-induced fibrosis in the kidney:questions and controversies.Am J Kidney Dis, 1,8(3):471-479.
    [27] Hou J, Xiong W, Cao L, et al.Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy:a Meta-analysis.Clin Ther, 5,7(9):2086-2103.
    [28] Bakris GL, Agarwal R, Chan JC, et al.Effect of finerenone on albuminuria in patients with diabetic nephropathy:a randomized clinical trial.JAMA, 5,4(9):884-894.
    [29] Ruilope LM, Agarwal R, Anker SD, et al.Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial.Am J Nephrol, 9,0(5):345-356.
    [30] Gagliardini E, Zoja C, Benigni A.Et and diabetic nephropathy:preclinical and clinical studies.Semin Nephrol, 5,5(2):188-196.
    [31] Mann JF, Green D, Jamerson K, et al.Avosentan for overt diabetic nephropathy.J Am Soc Nephrol, 0,1(3):527-535.
    [32] de Zeeuw D, Coll B, Andress D, et al.The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.J Am Soc Nephrol, 4,5(5):1083-1093.
    [33] Schievink B, de Zeeuw D, Smink PA, et al.Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.Eur J Prev Cardiol, 6,3(7):758-768.
    [34] Friedman AN, Wolfe B.Is bariatric surgery an effective treatment for type ii diabetic kidney disease?.Clin J Am Soc Nephrol, 6,1(3):528-535.
    [35] Chang AR, Chen Y, Still C, et al.Bariatric surgery is associated with improvement in kidney outcomes.Kidney Int, 6,0(1):164-171.
    [36] Shintani T, Klionsky DJ.Autophagy in health and disease:a double-edged sword.Science, 4,6(5698):990-995.
    [37] Kume S, Koya D.Autophagy:a novel therapeutic target for diabetic nephropathy.Diabetes Metab J, 5,9(6):451-460.
    [38] Yang D, Livingston MJ, Liu Z, et al.Autophagy in diabetic kidney disease:regulation, pathological role and therapeutic potential.Cell Mol Life Sci, 8,5(4):669-688.
    [39] Donate-Correa J, Tagua VG, Ferri C, et al.Pentoxifylline for renal protection in diabetic kidney disease.a model of old drugs for new horizons.J Clin Med, 9,8(3):287.
    [40] Cherney DZ, Perkins BA, Soleymanlou N, et al.Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.Circulation, 4,9(5):587-597.
    [41] Wanner C, Inzucchi SE, Lachin JM, et al.Empagliflozin and progression of kidney disease in type 2 diabetes.N Engl J Med, 6,5(4):323-334.
    [42] Marso SP, Daniels GH, Brown-Frandsen K, et al.Liraglutide and cardiovascular outcomes in type 2 diabetes.N Engl J Med, 6,5(4):311-322.
    引证文献
引用本文

刘裔凯,罗说明,邓敏,周智广.糖尿病肾病诊断与治疗新进展[J].中国动脉硬化杂志,2020,28(8):688~691, 706.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2020-04-10
  • 最后修改日期:2020-05-15
  • 在线发布日期: 2020-07-03

您是本站第 4760638 访问者

邮编：421001 传真：0734-8160523

电话：0734-8160765 E-mail：dmzzbjb@163.net

中国动脉硬化杂志 ® 2025 网站版权所有